ClearPoint Neuro, Inc.
CLPTHealthcareNASDAQMedical Devices · Last scanned May 30, 2026
Scan Results
Daily timeframeClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in. With a market capitalization of $380.0M, it sits in small-cap territory. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Market Cap
$380.0M
Beta
1.29
P/E (TTM)
—
P/E (Fwd)
-13.48
EPS (TTM)
$-1.00
EPS (Fwd)
$-0.94
ROE
-149.7%
ROA
-25.0%
Cash
$35.6M
Total Debt
$63.6M
Free CF
-$11.6M
52W Change
7.5%
Annual Financials
Cash vs Debt
ClearPoint Neuro, Inc. carries $63.6M in total debt against $35.6M in cash reserves — debt is roughly 1.8x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$11.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -149.7% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $20.6M (2022) to $37.0M (2025), reflecting a 80% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CLPT.